This study looks at the corneal endothelial cells (tiny cells in the eye) in people with neovascular age-related macular degeneration (nAMD). nAMD is a condition that affects the central part of your vision. The study will use a Port Delivery System (PDS), which is a small device placed in your eye to deliver medicine called ranibizumab every 24 weeks. To be part of this study, you need to have been diagnosed with nAMD in the last 18 months and have received certain eye treatments before. There are many factors that could prevent you from joining, like previous eye surgeries or other eye conditions.
- Length & Visits: The study requires regular visits, refilling the PDS every 24 weeks.
- Risks: You may not qualify if you have certain eye conditions or have had specific treatments before.
- Treatment: The study involves using a device and a specific medication to help manage nAMD.
How understandable was the trial content above?
Hard to understand
Easy to understand